Bristol Myers Squibb vs Eli Lilly
Add, change or remove companies; up to four.
KIRA’s take AI analyst
I put Bristol Myers Squibb and Eli Lilly side by side, using each one’s latest annual report. Here is what stands out:
- Eli Lilly is the larger business, with $65.2B of revenue in fiscal 2025 against $48.2B for Bristol Myers Squibb.
- Eli Lilly grew revenue faster (44.7%, against −0.2%).
- Bristol Myers Squibb turned more of its sales into free cash flow (26.7% FCF margin, against 13.8%).
- Eli Lilly earned a higher return on the capital invested in it (40.8%, against 15.2%).
- Investors pay more for each dollar of Eli Lilly’s earnings: a P/E of 42.9x against 13.6x for Bristol Myers Squibb.
Who comes out ahead
Of the 10 measures where higher (or lower) is clearly better, how many each company leads.
Bristol Myers Squibb
BMY
1/10
FCF margin
Eli Lilly
LLY
8/10
Revenue growth5-year growthGross marginNet marginReturn on capitalReturn on equityNet debt / EBITDAShare count change
Side by side
Best in the row
| Latest fiscal year | BMY FY25 | LLY FY25 |
|---|---|---|
| Size | ||
| Market cap | $126.2B | $1.14T |
| Revenue | $48.2B | $65.2B |
| Free cash flow | $12.8B | $9.0B |
| Net income | $7.1B | $20.6B |
| Growth | ||
| Revenue growth | −0.2% | 44.7% |
| 5-year growth | 2.5% | 21.6% |
| Share count change | 0.6% | −0.5% |
| Profitability | ||
| Gross margin | 71.1% | 83.0% |
| Operating margin | — | — |
| Net margin | 14.6% | 31.7% |
| FCF margin | 26.7% | 13.8% |
| Return on capital | 15.2% | 40.8% |
| Return on equity | 40.5% | 101.2% |
| Balance sheet | ||
| Net debt | $36.4B | $33.6B |
| Net debt / EBITDA | 2.4x | 1.2x |
| Dividends and buybacks | $5.0B | $9.5B |
| Valuation & quality | ||
| P/E | 13.6x | 42.9x |
| Piotroski F-score | 8 | 8 |
Ten years
Revenue
Operating margin
Free cash flow
Return on capital
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.